Table 1.

Summary of subjects included, sorted by centre, field strength, design, and treatment

Substudy	Centre	Field strength (T)	Nsubjects / group	Baseline (Day 1)	Follow-up (Day 2)	Study date	Study type
1	D	4.7	3	Saline	Saline	July 2018	P
2	E	7	3	Saline	Saline	Sept. 2018	P
3	G	7	3	Saline	Saline	July 2018	P
4	G	4.7	4	Saline	Saline	Sept. 2019	P
1	D	4.7	3	Saline	Rifampicin	July 2018	P
2	E	7	3	Saline	Rifampicin	Sept. 2018	P
3	G	7	3	Saline	Rifampicin	July 2018	P
4	G	4.7	4	Saline	Rifampicin	Sept. 2019	P
5	E	7	6	Vehicle	–	Sept. 2019	R
6	E	7	6	Vehicle	–	Oct. 2019	R
7	D	4.7	6	Vehicle	–	Sept. 2019	R
8	G	4.7	6	Vehicle	–	Nov. 2019	R
9	G	7	4	Vehicle	–	Oct. 2019	R
10	G	7	6	Vehicle	–	May 2019	R
11	G	7	6	Vehicle	–	Nov. 2019	R
12	G	4.7	4	Saline	–	Sept. 2019	R
13	G	7	3a	Saline	–	Sept. 2019	P
13	G	7	3b	Saline	–	Sept. 2019	P
13	G	4.7	3a	–	Saline	Sept. 2019	P
13	G	4.7	3b	–	Saline	Sept. 2019	P

Follow-up treatments on Day 2 for substudies 5–12 are beyond the scope of this paper. Substudies 1–4 have been duplicated to differentiate between those treated with saline at follow-up and those with rifampicin

^aThese subjects were imaged by the same centre using 7T at baseline and 4.7T at follow-up

^bThese subjects were imaged by the same centre using 4.7T at baseline and 7T at follow-up

P = prospective; R = retrospective